

FORM PTO-1390

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No.

2328-115

U.S. Application No. (if known, see 37 CFR 1.5)

09/462931

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

INTERNATIONAL APPLICATION NO. PCT/FI98/00550	INTERNATIONAL FILING DATE 24 June 1998 (24.06.98)	PRIORITY DATE CLAIMED 15 August 1997 (15.08.97)
---	--	--

**TITLE OF INVENTION**  
ISOLATED OSTEOCALCIN FRAGMENTS

**APPLICANT(S) FOR DO/EO/US:** HELLMAN, Jukka; KÄKÖNEN, Sanna-Maria; KARP, Matti;  
LÖVGREN, Timo; VÄÄNÄNEN, H. Kalervo; PETTERSSON, Kim

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3.  This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4.  A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5.  A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a.  is transmitted herewith (required only if not transmitted by the International Bureau).
  - b.  has been transmitted by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US)
6.  A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a.  are transmitted herewith (required only if not transmitted by the International Bureau).
  - b.  have been transmitted by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has **NOT** expired.
  - d.  have not been made and will not be made.
8.  A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.  An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10.  A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**ITEMS 11. TO 16. below concern other document(s) or information included:**

11.  An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12.  An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13.  A **FIRST** preliminary amendment.  
 A **SECOND** or **SUBSEQUENT** preliminary amendment.
14.  A substitute specification.
15.  A change of power of attorney and/or address letter.
16.  Other items or information:  
Small Entity Statement (Independent Inventors)  
Associate Power of Attorney

U.S. APPLICATION NO. IF Known, see 37 CFR 1.50  
**09/462951**INTERNATIONAL APPLICATION NO.  
PCT/FI98/00550ATTORNEY DOCKET NO.  
2328-115

428 Rec'd PCT/PPO 18 JAN 2000

17. [X] The following fees are submitted:

**Basic National Fee (37 CFR 1.492)(a)(1)-(5):**

Search Report has been prepared by the EPO or JPO	\$ 840.00
International preliminary examination fee paid to USPTO (37 CFR 1.482)	\$ 670.00
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))	\$ 690.00
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$ 970.00
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)	\$ 96.00

CALCULATIONSPTO USE ONLY**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$ 970.00

Surcharge of \$130.00 for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

Claims	Number Filed	Number Extra	Rate	
Total Claims	24 -20 =	4	X \$18.00	\$ 72.00
Independent Claims	1 - 3 =	-	X \$78.00	\$
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 1,042.00
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$ 521.00
<b>SUBTOTAL =</b>				\$ 521.00
Processing fee of \$130.00 for furnishing the English translation later [ ] 20 [ ] 30 than months from the earliest claimed priority date (37 CFR 1.492(f)).				\$
<b>TOTAL NATIONAL FEE =</b>				\$ 521.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$
<b>TOTAL FEES ENCLOSED =</b>				\$ 521.00
				Amount to be refunded \$
				charged \$

- a. [XX] A check in the amount of \$ 521.00 to cover the above fees is enclosed.
- b. [ ] Please charge my Deposit Account No. 02-2135 in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. [XX] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2135. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:  
 Jeffrey L. Ihnen, Esq.  
 Rothwell, Figg, Ernst & Kurz  
 555 13th St., N.W.  
 Washington, D.C. 20004  
 Phone: 202/783-6040

Signature

JEFFREY L. IHNNEN  
 Name \_\_\_\_\_  
 28.957  
 Registration Number \_\_\_\_\_  
 Dated: 18 January 2000

## SMALL ENTITY DECLARATION

1. Jukka HELLMAN 2. Sanna-Maria KÄKÖNEN 3. Matti KARP  
4. Timo LÖVGREN 5. H. Kalervo VÄÄNÄNEN 6. Kim PETTERSSON  
APPLICANT OR PATENTEE

SERIAL NO. \_\_\_\_\_ □ PATENT NO. \_\_\_\_\_ DOCKET NO. \_\_\_\_\_

Check one

of blocks

or 2)

1.  FILED OR ISSUED \_\_\_\_\_  
2.  SUBMITTED HEREWITH \_\_\_\_\_

FOR Isolated osteocalcin fragments  
(Insert Title)

I(we) hereby declare that I(we) am(are) entitled to the benefit of small entity status with respect to the above-identified application or patent for purposes of paying reduced fees under 35 USC 41(a) & (b) to the U.S. Patent and Trademark Office.

A. INDEPENDENT INVENTOR

I(we) qualify as (an) independent inventor(s) as defined in 37 CFR 1.9(c).

B. INDIVIDUAL NON-INVENTOR

I would qualify as an independent inventor as defined in 37 CFR 1.9(c) if I had made the invention.

C. SMALL BUSINESS CONCERN

I am  THE OWNER  AN OFFICIAL of the small business concern identified below and am empowered to act on behalf of the concern. The concern qualifies under 37 CFR 1.9(d) and 13 CFR 121.1301-1305. Rights under contract or law have been conveyed to and remain with the concern and are exclusive unless a checkmark is placed here  . All other rights belong to small entities as defined in 37 CFR 1.9.

D. NON-PROFIT ORGANIZATION

I am an official am empowered to act on behalf of the non-profit organization identified below. The organization qualifies under 37 CFR 1.9(e), sub section:  (1)  (2)  (3)  (4). Rights under contract or law have been conveyed to and remain with the organization and are exclusive unless a checkmark is placed here  . All other rights belong to small entities as defined in 37 CFR 1.9.

I(we) acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I(we) declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

A. INDEPENDENT INVENTOR(S)

Jukka Hellman

Name

Sanna-Maria Käkönen

Name

Matti Karp

Name

Timo Lövgren

Kalervo Väänänen

Kim Pettersson

Jukka Hellman

Signature

21.12.1999

Date

Sanna

Signature

21.12.1999

Date

Matti Karp

Signature

1999-12-20

Date

Timo Lövgren

Signature

21.12.1999

Date

Kalervo Väänänen

Kim Pettersson

22.12.1999

Date

20.12.1999

2328-115  
JLI:ch

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of )  
                              )  
Jukka HELLMAN et al.     ) U.S. National Phase of  
                              )  
Serial No. (to be assigned) ) PCT/FI98/00550  
                              )  
Filed: 07 January 2000    )  
                              )  
For: ISOLATED OSTEOCALCIN )  
                              )  
                              FRAGMENTS )

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Prior to examination of the above-identified application, filed concurrently herewith, please enter the following amendments:

IN THE CLAIMS:

Please amend the claims as follows:

Claim 1, line 20, at the end of the line, insert -- (SEQ ID NO:1) --.

Claim 4, line 3, delete ", 2 or 3".

Claim 7, line 7, change "claim 1" to -- SEQ ID NO:1 --.

Claim 8, line 1, delete "or 7".

Claim 9, line 1, delete "or 7".

Claim 10, line 1, delete "or 7".

Claim 11, line 1, delete "or 7".

Claim 12, lines 3-4, change "any of the claims 1 to 3" to -- claim 1 --.

-- 13 (amended). The method according to claim 12 characterized in that an immunoassay [according to any of the claims 6-11] is employed in which a sample containing said fragment is exposed to two monoclonal antibodies or recombinant antibody fragments which bind said gamma-carboxylated osteocalcin fragment. --

Please add the following new claims:

-- 14. The immunoassay according to claim 7 characterized in that the non-competitive immunoassay is carried out in either a one-step or a two-step incubation procedure. --

-- 15. The immunoassay according to claim 7 characterized in that the two monoclonal antibodies employed are the antibodies 2H9 and 6F9 that recognize the C-terminal and N-terminal epitopes on the fragment which was determined to be 3005. --

-- 16. The immunoassay according to claim 7 characterized in that the two monoclonal antibodies employed are the antibodies 6F9 and 3H8 that recognize the N-terminal and the C-terminal epitopes on the measured osteocalcin fragments (6-30 or 7-30). --

-- 17. The immunoassay according to claim 7 characterized in that the two monoclonal antibodies employed are the antibodies 6F9 and 3H8 that recognize the N-terminal and the C-terminal epitopes on the measured osteocalcin fragments (6-30 or 7-30). --

-- 18. A method for the measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders in an individual, characterized by quantitative determination of a fragment according to claim 2. --

-- 19. A method for the measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders in an individual, characterized by quantitative determination of a fragment according to claim 3. --

-- 20. The method of claim 13 characterized in that said monoclonal antibodies or recombinant antibody fragments are specific to epitopes that have been identified on the gamma-carboxylated fragment of osteocalcin, wherein said osteocalcin fragment spans either

- i) from the amino acid in position 7 to the amino acid in position 30, or
- ii) from the amino acid in position 6 to the amino acid in position 30 of the amino acid sequence described in claim 1, and that all three glutamic acids in the positions 17, 21 and 24 of said sequence are gamma-carboxylated. --

-- 21. The method according to claim 18 characterized in that an immunoassay is employed in which a sample containing said fragment is exposed to two monoclonal antibodies or recombinant antibody fragments which bind said gamma-carboxylated osteocalcin fragment. --

-- 22. The method of claim 21 characterized in that said monoclonal antibodies or recombinant antibody fragments are specific to epitopes that have been identified on the gamma-carboxylated fragment of osteocalcin, wherein said osteocalcin fragment spans either

- i) from the amino acid in position 7 to the amino acid in position 30, or
- ii) from the amino acid in position 6 to the amino acid in position 30 of the amino acid sequence described in claim 1, and that all three glutamic acids in the positions 17, 21 and 24 of said sequence are gamma-carboxylated. --

-- 23. The method according to claim 19 characterized in that an immunoassay is employed in which a sample containing said fragment is exposed to two monoclonal antibodies or recombinant antibody fragments which bind said gamma-carboxylated osteocalcin fragment. --

-- 24. The method of claim 23 characterized in that said monoclonal antibodies or recombinant antibody fragments are specific to epitopes that have been identified on the gamma-carboxylated fragment of osteocalcin, wherein said osteocalcin fragment spans either


- i) from the amino acid in position 7 to the amino acid in position 30, or
- ii) from the amino acid in position 6 to the amino acid in position 30 of the amino acid sequence described in claim 1, and that all three glutamic acids in the positions 17, 21 and 24 of said sequence are gamma-carboxylated. --

REMARKS

The claims have been amended to delete multiple dependencies and to insert reference to SEQ ID NO. No new matter has been added by the above amendments.

Respectfully submitted,

By



Jeffrey L. Ihnen, Reg. No. 28,957

Attorney for Applicants

ROTHWELL, FIGG, ERNST & KURZ, p.c.

Suite 701-E, 555 13th Street, N.W.

Washington, D.C. 20004

Telephone: (202)783-6040

Dated: 18 January 2000

ISOLATED OSTEOCALCIN FRAGMENTS

FIELD OF THE INVENTION

5 This invention relates to an isolated osteocalcin fragment derived from human urine, a monoclonal antibody or recombinant antibody fragment capable to bind said fragment, a cell line producing said monoclonal antibody, and an immunoassay for quantitative determination of said fragment. Furthermore, the invention concerns a method for the measurement of the rate of bone turnover (formation and/or

10 resorption) and/or for the investigation of metabolic bone disorders.

INTRODUCTION AND BACKGROUND

15 The publication and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.

Human osteocalcin (hOC), also designated bone Gla protein (BGP), is the most abundant noncollagenous protein synthesized by bone osteoblast (Poser et. al. J Biol Chem 1980; 255:8685-91). Although most of the synthesized osteocalcin is absorbed to bone hydroxyapatite by  $\gamma$ -carboxylated glutamic acids (Gla), a small part of it leaks into the blood stream where it can be detected (Price et al. J Biol Chem 1981; 256:12760-6). Part of the hOC found in blood is also thought to originate from the resorption process, when the hOC inside the bone tissues is released during bone degradation (Gundberg and Weinstein J Clin Invest 1986; 77:1762-7). Levels of circulating hOC have been widely used in the clinical investigations as a marker of bone formation (Power and Fottrell Crit Rev Clin Lab Sci 1991; 28:287-335) and serum hOC levels have been shown to correlate with

bone mineral density measurements (Yasamura et al. J Clin Endocrinol Metab 1987; 64:681-5).

The discordant results obtained from different hOC assays have hindered widespread usage of hOC in clinical applications (Masters et al. Clin Chem 1994; 40:358-63, Deftos et al. Clin Chem 1992; 38:2318-21, Delmas et al. J Bone Miner Res 1990; 5:5-11 and Diego et al. 1994; 40:2071-7). This phenomenon could partly be explained due to different assay formats i.e. sandwich vs. competitive assays or due to different detection techniques. Presently no calibration standard is available.

However, even if the same standard preparation is used, hOC levels measured in different laboratories cannot be directly compared (Delmas et al. J Bone Miner Res 1990). The diversity of hOC molecule itself in circulation has an evident contribution to its immunoreactivity in various assays. The vitamin K dependent  $\gamma$ -carboxylation degree of the glutamic acid residue varies (Poser et. al. J Biol Chem 1980; 255:8685-91). Impairment  $\gamma$ -carboxylation of hOC purified from bone has been indicated by Cairns and Price, J Bone Min Res 1994; 9:1989-97 and confirmed in our studies (Hellman et al. J Bone Miner Res 1996; 11:1165-75). When  $\text{Ca}^{2+}$  binds to Gla residues an  $\alpha$ -helix structure is known to form (Hauschka and Carr, Biochemistry 1982; 21:2538-47 and Atkinson et al. Eur J Biochem 1995; 232:515-21). Upon removal of  $\text{Ca}^{2+}$  with EDTA this helical conformation is destroyed. The conformation of decarboxylated OC lies somewhere between the random coil and helical form. Thus, in solution the peptide occurs as a flexible structure and a single conformation cannot be defined for it (Atkinson et al. Eur J Biochem 1995; 232:515-21). Peptide bonds between arginine residues 19 and 20 and between residues 43 and 44 are susceptible to tryptic hydrolysis leading to peptides 1-19, 20-43, 45-49, 1-43, and 20-49 which may be the main products of hOC breakdown in the circulation (Farrugia and Melick, Calcif Tissue Int 1986; 39:234-8, Hellman et al. J Bone Miner Res 1996; 11:1165-75 and Garnero et al. J Bone Miner Res 1994; 9:255-4).

Multiple immunoreactive forms of hOC have been discovered in circulation (Garnero et al. J Bone Miner Res 1994; 9:255-4) and also in urine (Taylor et al. J Clin Endocrin Metab. 1990; 70:467-72). The fragments of hOC can be produced either during osteoclastic degradation of bone matrix or as the result of the catabolic breakdown of the circulating protein after synthesis by osteoblasts. There is evidence that the production of some of the fragments found in urine occurs before renal clearance and is not a result of it (Taylor et al. J Clin Endocrin Metab. 1990; 70:467-72). Because of the rapid clearance from the circulation by glomerular filtration, the shOC (serum human OC) could reflect the acute changes in bone metabolism, while some of the uhOC (urine human OC) fragments might serve as an index of long term changes (Price et al. J Biol Chem 1980; 256:12760-6).

The first reported measurement of urine osteocalcin (Taylor et al. J Clin Endocrin Metab. 1990; 70:467 - 72) is based on competitive RIA utilizing polyclonal guinea pig antihuman OC antibodies for recognizing the immunoreactive OC fragments (Taylor et al. Metabolism 1988; 37:872-7.). The assay is said to be specific for the midmolecule epitope of hOC molecule according to information obtained from crossreactivity tests with tryptic fragments and synthetic peptide. The probable epitope for polyclonal antibody recognition is determined quite widely by the authors. It is concluded that the binding site of antisera is located in the midmolecule of the protein and probably involves amino acid 19 and at least a portion of the N-terminal sequence of the 20-43 tryptic digest fragment prior to amino acid 37. The assay is unable to distinguish decarboxylated hOC from carboxylated hOC in other words it is not dependent on the  $\gamma$ -carboxylation degree of glutamic acids 17, 21 and 24 in hOC. Furthermore the detailed characterization of the fragments detected by the assay is missing. In addition, this assay is not suitable for routine measurement of urine because the desalting of urine samples before measurement is inevitable for the proper function of RIA. Because of the

titer of immunoresponse to hOC varied remarkably with the individual animals, batch-to-batch variations in antibody production are likely to occur, which in term reduces the reproducibility of the assay. With this assay, in both serum and urine multiple immunoreactive OC-fragments have been detected. In addition, multiple 5 fragments were found in normal adult urine that were not detected in normal adult serum. However, the observed immunoreactive fragments were not characterized in detail. uhOC is better able to distinguish between children with high bone turnover and normal adults than serum hOC. The correlation between the serum and the urine samples as measured by the uhOC RIA was good indicating that the assay is 10 detecting osteocalcin originating from the formation process ( $r = 0.83$ ,  $p < 0.01$ ). Besides this, even better correlation was obtained between uhOC and serum alkaline phosphatase measurements. (Taylor et al. J Clin Endocrin Metab. 1990; 70:467-72). A disadvantage of using shOC as a bone metabolism marker is the obvious diurnal 15 variation of hOC concentration (Gundberg et al. J Clin Endocrinol Metab 1985; 60:736-9). One solution for the problem might be to determine the hOC values in 24-hour urine pool.

In the menopause the concentration of serum osteocalcin is increased. The level of increase is partly dependent on the differences in the osteocalcin assays employed 20 or the population studied, but is generally about 30 -50 % above the premenopausal values (Ravn et al. Bone 1996; 19:291-8, Bonde et al. J Clin Endocrinol Metab 1995; 80:864-8, Garnero et al. J Bone Miner Res 1996; 11:337-49, Åkesson et al. J Bone Miner Res 1995; 18:23-9). Generally, the concentration of hOC decreases during antiresorptive treatment like hormon replacement therapy (HRT) (Chen et al. 25 J Bone Miner Res 1996; 11:1784-92, Hodzman et al. J Clin Invest 1993; 91:1138-48). Serum hOC measurements are therefore utilized for monitoring the effectiveness of treatment and also in the pharmaceutical studies designing new antiresorptive drugs. High turnover in bone metabolism in children and especially, in puberty increases the hOC concentrations remarkably (Taylor et al. J Clin

Endocrin Metab. 1990; 70:467-72, Jaouhari et al. Clin Chem 1992; 38:1968-74, Gundberg et al. Clin Chim Acta 1983; 128:1-8).

## SUMMARY OF THE INVENTION

5

This invention relates to an isolated osteocalcin fragment derived from human urine, said fragment being characterized in that at least one of the glutamic acids in the position 17, 21 and 24 of the amino acid sequence

10		6      7	
	Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-		
	Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-		
15		17                          21                          24	
	Glu-Pro-Arg-Arg-Glu-Val-Cys-Glu-Leu-		
		30	
20	Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-		
	Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-		
	Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val		

25 is gamma-carboxylated.

According to another aspect, the invention relates to a monoclonal antibody or recombinant antibody fragment having the capability of binding the human gamma-carboxylated osteocalcin fragment as defined above.

30

According to a third aspect, the invention concerns a cell line producing said monoclonal antibody.

According to a fourth aspect, the invention relates to an immunoassay for quantitative determination of a gamma-carboxylated osteocalcin fragment defined above, said immunoassay being characterized in that a sample containing said fragment is exposed to a monoclonal antibody or recombinant antibody fragment  
5 which binds said gamma-carboxylated osteocalcin fragment.

According to a fifth aspect, the invention relates to a method for the measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders in an individual, said method being based on the  
10 quantitative determination of an osteocalcin fragment as defined above.

This is the first report of isolation and characterization of osteocalcin fragments in urine. Three two-site assay detecting these hOC fragments in urine utilizing well characterized reagents are described and validated with clinical samples. The  
15 described non-competitive immunoassays are the first assays sensitive enough for the detection of urine osteocalcin fragments in routine clinical measurements. Urine hOC discriminates the pubertal subjects from the adult subjects better than the serum hOC. In addition, an outstanding clinical utility for the discrimination of the postmenopausal group from the premenopausal group is observed. Furthermore,  
20 hOC concentrations in postmenopausal group receiving antiresorptive treatment are significantly lower when compared to the concentrations in control postmenopausal group. Serum and urine samples from the same individuals do correlate using the same assay but substantial differences do occur. This result indicates that the fragments of hOC in urine might reflect different state of bone metabolism than  
25 fragments of hOC in serum.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 A shows the nucleic acid and the amino acid sequences of the synthetic human osteocalcin insert. Figure 1 B shows plasmid vector pGEX-3X (Pharmacia).

5 The arrow indicates the SmaI-ligation site of the hOC insert. The pfXa (protease factor Xa) cleavage site is located after the Ile-Glu-Gly-Arg -sequence.

Figure 2 A shows SDS-PAGE and Figure 2 B shows Western blotting analysis of various osteocalcin forms. Lane 1. Low molecular weight (kDa) markers, lane 2.

10 Affinity-purified GST (glutathione S-transferase), lane 3. hOC purified from human bone, lane 4. bOC (bovine osteocalcin), lane 5. Affinity-purified GST-rhOC (GST-recombinant human osteocalcin fusion protein), lane 6. Chromatographically purified rhOC (recombinant human osteocalcin) i.e. the cleavage product from incubation of GST-rhOC with pfXa.

15 Figure 3 is a schematic representation of the approximate epitopes recognized by the Mabs used in two-site hOC assays. The molecule has been divided into four epitope areas each of which is being recognized by different Mabs. Circled numbers indicate the number of the hOC specific immunoassay. Amino- and carboxyterminal 20 amino acids have been marked as 1 and 49, respectively. The protease-sensitive sites have been indicated as R-R (arginine-arginine), the three Gla-residues are shown as well as the disulphide bridge (C-C).

25 Figure 4 shows the determination of immunoreactive uhOC fragments in normal pubertal urine. Urine was subjected to immunoaffinity chromatography and solid phase extraction before HPLC fractionation. The fractions were measured for immunoreactive material with hOC specific assay #7. The squares refer to osteocalcin and the triangles to acetonitrile.

Figures 5 A to 5 E show characteristics of the immunoreactive hOC fragments isolated from normal pubertal urine. Fig. 5 A: Mass analysis of the most prominent fragment 44 isolated from urine spanning the amino acid residues 7-30 (Gly-Asp). Fig. 5 B: Mass analysis of the urine hOC fragment 46 spanning the amino acid residues 6-30 (Leu-Asp). Fig. 5 C: Mass analysis of the urine hOC fragment 43. Fig. 5 D: Mass analysis of the urine hOC fragment 47. Fig. 5 E: Characteristics of the hOC fragments isolated in urine and characteristics of intact hOC.

Figure 6 shows the difference between the hOC concentrations in serum and urine between pubertal and adult samples as measured by the hOC IFMAs. hOC concentration in urine and serum samples was clearly higher in pubertal girls than in premenopausal women as measured with the hOC immunoassays.

Figures 7 A and 7 B demonstrate hOC levels in pre-, postmenopausal and postmenopausal with HRT groups of women measured with the IFMAs. The concentrations have been obtained in serum (Fig. 7 A) and urine (Fig. 7 B) samples of adult females. In the urine samples the differences between menopausal groups were more obvious than in the serum samples even as measured with the same combination of Mabs.

Figures 8 A to 8 D show correlations between different assays measured in urine and serum samples from adult female panel. Fig. 8 A: Correlation between uhOC as measured by the assays #4 and #7. Fig. 8 B: Correlation between uhOC as measured by the assays #7 and #9. Fig. 8 C: Correlation between serum and urine samples as measured by the assay #7. Fig. 8 D: Correlation between serum and urine samples as measured by the assay #4.

## DETAILED DESCRIPTION OF THE INVENTION

According to a preferred embodiment, the isolated osteocalcin fragment derived from human urine is a fragment spanning i) from the amino acid in position 7 to the amino acid in position 30, or ii) from the amino acid in position 6 to the amino acid in position 30 of the amino acid sequence

Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-  
 Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-  
 Glu-Pro-Arg-Arg-Glu-Val-Cys-Glu-Leu-  
 Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-  
 Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-  
 Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val

25 where all three glutamic acids in the positions 17, 21 and 24 of said sequence are  
gamma-carboxylated.

The preferred monoclonal antibody or recombinant antibody fragment has a specificity to epitopes that have been identified on the gamma-carboxylated fragment of osteocalcin, wherein said fragment spans either

- i) from the amino acid in position 7 to the amino acid in position 30, or
- ii) from the amino acid in position 6 to the amino acid in position 30

of the amino acid sequence described above, and that all three glutamic acids in the positions 17, 21 and 24 of said sequence are gamma-carboxylated.

The preferred immunoassay according employs a monoclonal antibody or recombinant antibody fragment having the said specificity.

5 The preferred immunoassay is a non-competitive immunoassay employing at least two different monoclonal antibodies or recombinant antibody fragments.

The non-competitive immunoassay is preferably carried out in either a one-step or a two-step incubation procedure.

10

Particularly preferable immunoassays are those where the two monoclonal antibodies employed are

15 i) the antibodies 2H9 and 6F9 that recognize the C-terminal and N-terminal epitopes on the fragment which was determined to be 3005.

ii) the antibodies 6F9 and 1C4 that recognize the N-terminal and the C-terminal epitopes on the measured osteocalcin fragments (6-30 or 7-30), or

20 iii) the antibodies 6F9 and 3H8 that recognize the N-terminal and the C-terminal epitopes on the measured osteocalcin fragments (6-30 or 7-30).

All the disclosed assays are highly sensitive and are based on widely characterized reagents. Difference in hOC concentration between the premenopausal and the 25 pubertal group was clearly higher in urine samples than in serum samples. All the hOC assays discriminated the menopausal groups effectively using either serum or urine specimens. Due to their ability to detect different hOC forms, these assays should be of interest in monitoring various disease states, particularly of bone metabolism diseases. The assays are thus especially useful in methods for the

measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders.

## 5 EXPERIMENTAL

### 1. Production of the recombinant osteocalcin fusion protein

#### Materials

10 Molecular biology reagents and enzymes were obtained from Pharmacia Biotech, Uppsala, Sweden or from New England Biolabs. Expression vector pGEX-3X was obtained from Pharmacia Uppsala, Sweden. Escherichia coli XL1-Blue strain (recA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, lac, F' proAB, lacI<sup>q</sup>ZDM15,

15 Tn10 (tet<sup>r</sup>) was used for the expression of the GST-rhOC fusion protein. L-broth culture medium contained 10 g/l Bacto<sup>®</sup> Tryptone (Difco laboratories, Michigan, USA), 5 g/l Bacto<sup>®</sup> Yeast extract (Difco) and 5 g/l NaCl, pH 7.4. Isopropyl-1-thio-β-D-galactoside, IPTG (Sigma Chemical CO, USA) was used for induction. PBS buffer consisted of 150 mM NaCl, 16 mM Na<sub>2</sub>HPO<sub>4</sub>, 4 mM NaH<sub>2</sub>PO<sub>4</sub>, pH 7.3.

20 PMSF and reduced glutathione were obtained from Sigma and protease factor Xa, pfXa from New England Biolabs. Glutathione Sepharose<sup>®</sup> 4B column (bed volume 8 ml) was obtained from Pharmacia.. The size separation of the proteins was done with SDS-PAGE 25 % gradient Phastgel and using Low molecular weight markers for standardization (Pharmacia). Bovine osteocalcin (bOC) was obtained from

25 Biodesign International, Kennebunkport, ME. A commercial anti-bOC Mab BD (Biodesign) was used as a primary antibody and a horseradish peroxidase linked anti-mouse immunoglobulin raised in sheep was used as a second antibody

(Amersham, Buckinghamshire, England). ECL Western blotting reagents (Amersham) were used for visualization according to manufacturer's suggestions.

5

### Equipment

Human osteocalcin oligomers and the oligomer primers designed for sequencing were synthesized on an Applied Biosystems (Foster City, CA) oligonucleotide synthesizer. Nucleic acid sequencing was done with T7 Sequencing Kit and Macrophor equipment from Pharmacia. The electroporation was done with Gene pulser (Bio-Rad, Richmond, CA). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was run with PhastSystem (Pharmacia). Matrix assisted laser desorption (MALDI-MS) mass spectrometer (LASERMAT<sup>®</sup>, Finnigan MAT Ltd., U.K.) was employed to obtain the mass of the peptides. A protein sequencer (Applied Biosystems model 477A) equipped with an on-line Applied Biosystems model 120A PTH amino acid analyzer was employed for the NH<sub>2</sub>-terminal amino acid analyses. Reverse phase chromatography was done using a C8 RP-300 column (4.6 x 100 mm) (Applied Biosystems). The proteins were electroblotted onto Hybond<sup>TM</sup>-C extra nitrocellulose membranes (Amersham) using PhastTransfer<sup>TM</sup> Semi-dry Transfer Kit (Pharmacia) according to PhastSystem<sup>TM</sup> manual.

### Plasmid construction

25

Synthetic human osteocalcin oligomers (Fig. 1A), each containing 88 nucleic acids (8 of them being complementary to each other) were hybridized at RT after phosphorylation of the ends. The single-stranded ends were filled by 1 U of Klenow

polymerase and 100 µM of each deoxynucleotide (30 minutes incubation at 37 °C) to create a 160 base pair human osteocalcin insert, which contains a stop codon and a PstI restriction enzyme site at the 3' end of the gene (Fig. 1A). The blunt-ended insert was ligated in SmaI-digested, dephosphorylated prokaryotic expression vector, pGEX-3X (Fig. 1B). The recombinant plasmid was transformed into E. coli and the resulting vector was confirmed by restriction enzyme digestion and nucleic acid sequencing. All molecular biology protocols were according to Sambrook et al. Molecular Cloning, a Laboratory Manual, Second Edition, 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

10

### **Expression of the GST-rhOC fusion protein**

Transformed E. coli cells were grown at 37 °C in 250 ml of L-broth containing 100 µg/ml ampicillin to an A<sub>600</sub> = 0.5 and then IPTG was added to a final concentration 15 of 0.5 mM. Induced cells were grown for an additional 2 h and were collected by centrifugation, disrupted by sonication on ice in PBS buffer containing 2 mM PMSF, Sigma and 1 mM EDTA as protease inhibitors. After sonication, Triton-X-100 (1 % v/v) was added. The sonicate was clarified by centrifugation (10,000g, 20 min, 4 °C) and filtered through a 0.45 µm filter before applying it to an equilibrated 20 Glutathione Sepharose® 4B column according to manufacturer's suggestions.

### **Purification of the recombinant human osteocalcin**

After concentration, the eluate containing the GST-rhOC fusion protein was 25 incubated with pfXa in 20 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl<sub>2</sub>, pH 8.0, using a protease to substrate ratio of 0.5 % (w/w) for 30 min at RT to release the rhOC portion (Nagai and Thøgersen Nature 1984; 309:810-2). Then rhOC was separated from the mixture reverse phase chromatography using a C8 RP-300

column. The optimization of the rhOC purification has been described in detail by Käkönen et al. (1996).

### Verification of the protein products

The expression vector contained the entire sequence of the hOC gene fused in frame to the 3' end of the *Schistosoma japonicum* glutathione S-transferase gene (Smith and Johnson Gene 1988; 67:31-40) as verified by nucleic acid sequencing. The resulting fusion protein contains three additional amino acids between the protease factor Xa cleavage site and the first amino terminal tyrosine of the hOC gene (Fig. 1B). The molecular mass of the reverse phase HPLC purified rhOC was 6068.1 as determined by mass spectrometry. This value is consistent with the predicted mass calculated from the amino acid sequence (6064.8, rhOC has a extension of three aminoacid residues (Gly-Ile-Pro) because of the pfXa cleavage site in pGEX-3X plasmid (Fig. 1 A and B.). Purified GST-rhOC and rhOC were compared with hOC purified from bone and with bOC using SDS-PAGE and Western blotting analysis. The size of purified GST-rhOC (32 kDa) obtained by SDS-PAGE is in accordance with that expected from a fusion protein containing GST (26 kDa, Smith and Johnson Gene 1988; 67:31-40) and rhOC (6068.1 Da). Purified rhOC migrates similarly both to hOC purified from human femurs and bOC on SDS-PAGE (Fig. 2A, lanes 3, 4 and 6, respectively). In Western blotting experiment, Mab BD binds to hOC and bOC (Fig. 2B, lanes 3 and 4, respectively) and also to the both recombinant forms, GST-rhOC and rhOC (Fig. 2B, lanes 5 and 6, respectively). A 64 kDa band is also observed from the fusion protein sample (Fig. 2B, lane 5) which probably indicates a dimeric form of GST-rhOC. Mab BD does not bind to GST or to any of the molecular weight markers (Fig. 2B, lanes 1 and 2, respectively).

**2. Production of the osteocalcin monoclonal antibodies****Materials and equipment**

5     GST-rhOC used as an immunogen was produced as described (Käkönen et al. Prot Exp Purif 1996; 3:137-44). Bovine osteocalcin (bOC) was obtained from Biodesign International, Kennebunkport, ME. Freund's complete adjuvant (Fca) and Freund's incomplete adjuvant (Fia) were obtained from Sigma Immuno Chemicals, St Louis, MO. The Optimem-1 with glutamax-1, Dulbecco's Modified Eagle Medium  
10   (DMEM, 10 x liquid), L-glutamine, sodiumpyruvate (tissue culture tested), sodiumbicarbonate (tissue culture grade) and penicillin-streptomycin (P/S) solution were purchased from Gibco BRL, Life Technologies, Grand Island, NY, Hepes from Boehringer Mannheim, Germany and the fetal bovine serum from Hyclone, Logan, UT and were used as components in culture mediums. Reagents and  
15   equipment used for screening the hOC specific hybroma cell lines were obtained from Wallac Oy, Turku, Finland except the Europium-labeled hOC was prepared according to Hellman et al. (J Bone Miner Res 1996; 11:1165-75).

Pristane (2,6,10,14-tetramethyl pentadecan) used for the production of Mabs as  
20 ascitic fluid was obtained from Aldrich-Chemie, Steinheim, Germany. Tecnomouse hollow-fiber bioreactor used for the large scale production of Mabs was obtained from Integra Biosciences AG, Wallisellen, Switzerland and Protein A agarose Affigel® for the purification of the Mabs was from Bio-Rad, Richmond, CA.

**25   Immunization of the mice and screening of the hOC specific Mabs**

The employing of recombinant OC fusion protein as an immunogen has been described earlier (Matikainen et al In "Animal cell technology: Developments towards the 21st century" 1995; pp. 475-9). Ten months old male Balb/c mouse was

intraperitoneally immunized with 413 µg GST-rhOC antigen (corresponding to 75 µg of rhOC portion) mixed with Fca. The mouse was boosterd 15 weeks later with 358 of the same antigen (60 µg of rhOC) mixed in Fia. The final booster dose, 110 µg antigen (20 µg of rhOC) in PBS was given i.p. after 8 weeks.

5

Bovine osteocalcin was coupled to keyhole limpet hemocyanin (KLH) as described (Young et al. Prostaglandines 1982; 23:603-13). Two three-month-old Balb/c male mice were i.p. immunized with 50 µg of bOC-KLH antigen mixed with Fca. The mice were boosterd with the same amount of antigen in Fia. The final booster dose, 10 10 µg bOC-KLH in PBS, was given intravenously.

Three days after the final boosterd the splenocytes were fused to mouse myeloma cells SP 2/0 as described in more detail earlier (Lilja et al. Clin Chem 1991; 37:1618-25). The hybridomas were grown in Optimem-1 with glutamax-1 containing 20 % of fetal bovine serum. The hOC specific Mabs were screened with immunofluorometric assay (IFMA) using rabbit antimouse Ig microtitration wells and hOC labeled with Europium as described earlier (Matikainen 1995).

#### **Large scale production and purification of the Mabs**

20

Before large scale production of Mabs the positive hybridomas were cloned at least twice by the limiting dilution method. Optimem-1 with glutamax-1 supplemented with 20 % of fetal bovine serum was used as culture medium. Cell lines 2H9F11F8 (2H9) and 6F9G4E10 (6F9) obtained from the GST-rhOC immunization and 25 3G8E1F11 (3G8), 1C4B1D7E7 (1C4) and 3H8H2D2A12F12 (3H8) obtained from bOC immunizations were selected for further characterization. The Mabs were produced as ascites fluid in Balb/c mice primed with pristane and in Tecnomouse hollow-fiber bioreactor. DMEM (1 x solution) supplemented with L-glutamine, Hepes, sodiumpyruvate, sodiumbicarbonate and P/S was used as a culture medium

in intracapillary circulation. Optimem-1 with glutamax-1 supplemented with 2.5 % fetal bovine serum was used as a harvesting medium in extracapillary space.

Produced Mabs were purified by Protein A agarose chromatography using Affigel<sup>®</sup> purification kit according to manufacturer's suggestions.

5

10 **3. Epitope mapping, characterization of the Mabs and two-site assays**

**Materials**

In the subclass determination of the Mabs, the streptavidin-coated microtiter plates  
15 were obtained from Wallac Oy and biotinylated rat antimouse Ig subclass specific  
Mabs from Serotec, Oxford, England. For epitope mapping the synthetic osteocalcin  
peptide 7-19 containing Glu at residue 17 was purchased from Bachem, Switzerland  
and bovine osteocalcin (bOC) was obtained from Biodesign International,  
Kennebunkport, ME. Osteocalcin from human femurs was purified by modifying a  
20 previously described method (Gundberg et al. Meth Enzymol 1984; 107:516-544) as  
explained in detail by Hellman et al. (1996). Also the carboxypeptidase Y digestion,  
trypsin digestion, alkylation and decarboxylation of hOC has been described earlier  
(Hellman et al. 1996). The detailed characterization of the hOC and its  
modifications is described by Hellman et al. (1996). The recombinant forms of  
25 osteocalcin were produced as explained in section 1. The production and  
purification of a truncated form of rhOC (del. rhOC) (lacking 10 COOH-terminal  
amino acid residues) from a gene carrying a stop mutation in the structural region  
was performed under similar conditions. Both rhOC and del rhOC have an

extension of three amino acid residues in their NH<sub>2</sub> termini; in addition, they lack the  $\gamma$ -carboxylation characteristic of hOC isolated from bone.

Reagents for biotinylation, biotin isothiocyanate (BITC) and labeling, europium(III) chelate of 4-[2(-4-isothiocyanatophenyl)ethynyl]-2,6-bis{[N,N-bis(carboxymethyl)amino]methyl}pyridine (Takalo et al. Helv Chim Acta 1993; 76:877-83) were from Wallac Oy. Streptavidin coated microtiter plates, Delfia® Buffer, Delfia® Wash Solution, Delfia® Enhancement Solution and Delfia® Research Fluorometer, Model 1234 used in IFMA measurements were obtained from Wallac Oy. Reagents and equipment used in the immunoassays were similar throughout the study.

### Characterization of the Mabs

Labeling of the peptides for subclass determination and epitope mapping was done according to Hellman et al. 1996. The Mabs 6F9, 3G8, 1C4 and 3H8 belonged to subclass IgG1 and the Mab 2H9 to subclass IgG2a as determined according to Matikainen et al., 1995.

Mabs were characterized for their binding to Eu-labeled intact hOC, bOC and tryptic or synthetic peptides as described (Hellman et al. 1996). The antibodies 1C4 and 3H8 obtained by immunization with bOC conjugated to KLH recognized the tryptic 20-43 fragment. For Mab 3G8, also obtained from bOC immunizations, no specific binding site could be located using labeled peptides. Also, labeling of intact bOC and hOC abolished their immunoreactivity with 3G8, suggesting either that intact Tyr (1) is needed for efficient binding or that the Eu-chelate causes steric hindrance. Unlabeled intact hOC or bOC were, however, easily recognized by this antibody in a two-site format with Mab 2H9. Mab 6F9 recognized the tryptic 1-19 and synthetic 7-19 peptides. Mab 2H9 recognized the tryptic 20-43 peptide.

Summary of the Mabs in Table 1. According to information obtained an epitope map was created (Fig.3).

5

**Table 1. Characterization of Mabs against**

Hybridoma clone	Immunogen	Immunoglobulin class H-chain <sup>a</sup>	Eu-labeled OC forms recognized <sup>b</sup>					
			Eu-hOC	Eu hOC 1-19	Eu-hOC 7-19	Eu-hOC 15-31	Eu-hOC 20-43	Eu-bOC
2H9	rGST-hOC	IgG2a	+	-	-	+	+	+
3G8	bOC-KLH	IgG1	+ <sup>c</sup>	-	-	-	-	+ <sup>c</sup>
3H8	bOC-KLH	IgG1	+	-	-	+	+	+
1C4	bOC-KLH	IgG1	+	-	-	+	+	+
6F9	rGST-hOC	IgG1	+	+	+	+	-	-

<sup>a</sup> Alk light chains.

<sup>b</sup> Measured according to Hellman et al. 1996 c Mab 3G8 recognizes unlabeled hOC and bOC when tested with

<sup>c</sup> Mab 3G8 recognizes unlabeled hOC and bOC when tested with two-site

### Biotinylation and Eu labeling of the Mabs

10

In order to create two-site combination assays the Mabs 3G8, 2H9 and 6F9 were biotinylated with BITC and the Mabs 2H9, 6F9, 1C4 and 3H8 were labeled with europium(III) chelate in reaction conditions previously described (Hellman et al, 1996). The two-site immunoassay utilized time-resolved fluorometry using lanthanide chelate labels, like europium, as a detection system (Soini and Lövgren CRC Crit Rev Anal Chem. 1987; 18:105-53).

15

### Characterization of the two-site assays

20

Four of the two-site combinations were validated in more detail by determination of the crossreactivities to the alkylated hOC, decarboxylated hOC, carboxypeptidase Y-digested hOC, recombinant hOC and truncated recombinant hOC. According to

information obtained by crossreactivity determination and the epitope mapping the assay # 2 (bio-3G8/Eu-2H9) was considered specific for the full length, intact hOC molecule. The assays # 4 (bio-2H9/Eu-6F9), #7 (bio-6F9/Eu-1C4) and #9 (bio-6F9/Eu-3H8) were able to detect the full length hOC and also the large NH<sub>2</sub>-terminal fragment. Assay #4 measured both  $\gamma$ -carboxylated and fully decarboxylated form of hOC. The #9 and #7 assays distinctively preferred the carboxylated form of hOC. Determination of the affinity constants of labeled Mabs were done according to Hellman et al. 1996 using Scatchard analysis (Scatchard, Ann NY Acad Sci 1949; 51:660-72). Characteristics of the assays are summarized in Table 2.

10

Table 2. Characteristics of the two-site IFMAs of

Combination number	Capture Mab	Tracer Mab	$K_a$ (x 10 <sup>6</sup> L/mol) <sup>a</sup> of tracer Mab in	
			AB	+ 5 mM EDTA + 25 mM Ca
2	3G8	2H9	3.30	3.40
4	2H9	6F9	0.7	0.83
7	6F9	1C4	0.13	0.11
9	6F9	3H8	0.68	0.64

Combination number	Capture Mab	Tracer Mab	Crossreactivities in percent (w/w)				
			hOC	dec. hOC	rhOC	CPY hOC	del. rhOC
2	3G8	2H9	100	64	69	9	1
4	2H9	6F9	100	46	44	150	65
7	6F9	1C4	100	19	6	169	18
9	6F9	3H8	100	8	7	156	6

<sup>a</sup> Affinities determined according to Scatchard as described by

<sup>b</sup> Measured as described by Hellman et

15 In addition to two-site non-competitive assays, the hOC specific antibodies could be utilized in competitive assays as a capture antibody. In competitive assay hOC fragments in urine compete with the Eu-labeled hOC for binding to the limited

number of capture Mabs. With Mabs 2H9, 1C4 and 3H8 also Eu-labeled bOC could be used due to crossreactivities explained in Table 1.

## 5    4. Optimized assay procedures

### Materials and equipment

The employed Mabs have been characterized in the previous section. In addition to  
10 Mabs produced in hybridoma cell culture, also recombinant antibody fragments could be used in the assay concept. hOC and CPYhOC (Carboxy-peptidase Y digested hOC) used for the standardization of the assays were produced as explained in section 3. DTPA (diethylenetriaminepentaaceticacid) -treated BSA in TSA-buffer (50 mM Tris-HCl, 150 mM NaCl, 15 mM NaN<sub>3</sub>, pH 7.75) used as a diluent in standardization was obtained from Wallac Oy. Materials and equipment  
15 used in the OC IFMAs have been listed in the section 3.

### All-in-one assays optimized for serum samples

20 10 µl of samples and standards were pipetted streptavidin coated microtiter plates. The calibration curve was prepared using purified hOC in 7.5 % (w/v) DTPA-treated BSA in TSA buffer as a standard covering the range from 0.5 to 80 ng/ml. Then a mixture of biotinylated and Eu labeled Mabs in 50 µl of Delfia® Buffer was added to the wells. The amount of capture or tracer Mab was 200 ng/well except  
25 100 ng/well of tracer Mabs were used in assays #2 and #9. 5 mM EDTA was added into Delfia® Buffer in assays #4, #7 and #9. The plates were shaken for 2 h at RT followed by washing six times with Delfia® Wash Solution. To detect the Eu fluorescence, 200µl of Delfia® Enhancement solution per well was added. Prior to

the measurement with the Delfia® Research Fluorometer the plates were shaken 30 min at RT.

The lower limit of the detection of the different assays were determined based on  
5 two standard deviations of the background signal produced by the standard diluent and was under 0.1 µg/L for each assay. The developed IFMAs showed a linear response of over four orders of magnitude and were highly reproducible.

#### **Osteocalcin assays optimized for urine samples**

10 The calibration curve for assay #4 was prepared using purified hOC purified hOC in 7.5 % (w/v) DTPA-treated BSA in TSA buffer as a standard covering the range from 0.05 to 16 ng/ml. Carboxy-peptidase Y digested hOC (CPY hOC) in the same diluent covering the range from 0.05 to 16 ng/ml was used for standardization for  
15 the assays #7 and #9.

First, 400 ng of biotinylated capture Mab in 50 µl of Delfia® Buffer was pipetted to the streptavidin well. After 30 minutes shaking at room temperature the excess capture Mab was removed by two washings using Delfia® Wash Solution. Before  
20 the adding labeled tracer Mab in 50µl Delfia® Buffer, the standard or sample was pipetted in 10 µl volume. 100 ng of labeled tracer was used except in assay #7 where 200 ng/well of Eu-1C4 was used. After two hours shaking at room temperature, the wells were washed six times and 200µl of Delfia® Enhancement solution per well was added. Prior to the fluorescence measurement, the plate was  
25 shaken 30 minutes at room temperature. The assays were highly linear and reproducible. The lowest detection limits were under 0.1 µg/L.

## 5. Isolation and characterization of urine osteocalcin fragments

### Materials and equipment

5 Carboxy-peptidase Y digested hOC (CPY hOC) used for standardization of the  
urine IFMAs was produced as explained in section 3. Immunoaffinity  
chromatography coupled with purified 6F9Mab (section 2) using Affi-Gel Hz  
Immunoaffinity kit from Bio-Rad, a C-18 solid phase extraction cartridge  
(Millipore) and a C-4 reverse phase HPLC column (Vydac, Hesperia, CA, U.S.A.)  
10 were used for the isolation of uhOC fragments. Matrix assisted laser desorption  
MALDI-TOF mass spectrometer (LASERMAT<sup>R</sup>, Thermo Bioanalysis Ltd., U.K.)  
was employed for mass determinations and a protein sequencer (Applied  
Biosystems model 477A) equipped with an on-line Applied Biosystems model 120A  
PTH amino acid analyzer was used for the NH<sub>2</sub>-terminal amino acid sequence  
15 analyses.

### Sample collection and uhOC IFMA

Urine pool was collected in the morning from one healthy male volunteer aged 13  
20 years and stored at +4 °C. Within three hours the pool was aliquoted and frozen at -  
70 °C. Later it was stored at -20 °C. Urine pool was thawed, centrifuged and  
filtrated before subjected to any isolation steps.

Immunoreactive uhOC in both urine pool and different steps of isolation process  
25 was measured with a two-site immunoassay recognizing, not only the intact hOC,  
but also the N-terminal mid-fragment of hOC (amino acid residues 1 - 43) (Fig. 3).  
The assay used monoclonal antibodies (Mabs) 6F9 and 1C4 as a capture and tracer  
Mab, respectively (combination #7). The calibration curve was prepared using  
carboxy-peptidase Y digested hOC (CPY hOC) as a standard. The amount of

immunoreactive uhOC in puberty urine pool was 100 ng/ml. Also the assays #9 (Mab combination 6F9/3H8) and #4 (Mab combination 2H9/6F9) were utilized to determine the immunoreactive fragments as described in section 4.

5

### Isolation of osteocalcin fragments

First, immunoreactive osteocalcin fragments from puberty urine pool were adsorbed by immunoaffinity chromatography. The gel matrix was covalently coupled with hOC Mab 6F9 recognizing an N-terminal epitope (Fig. 3). After adsorption the bound fragments were eluted by 0.1 M acetic acid and adsorbed onto a C-18 solid phase extraction cartridge, again eluted with 80 % acetonitrile (AcN) and evaporated. In the immunoaffinity chromatography, over 90 % of the immunoreactive uhOC was adsorbed onto the 6F9 coupled gel. In the elution step (including adsorption steps and washings of the gel) 10 % of the adsorbed uhOC was eluted. To improve the yield more urine was applied onto the affinity column and then the eluent was recycled 5 hours through the affinity column attached to two C-18 solid phase extraction cartridges all connected to each others in series. After evaporation the C-18 solid phase eluent contained at least 2 mg/ml of immunoreactive uhOC as measured by the urine hOC assay utilizing Mab combination #7.

Next, the sample containing the immunoreactive fragments was applied onto a Vydac C-4 (2.1 mm x 150 mm) reverse phase HPLC column, eluted with an acetonitrile gradient (Fig. 4) and the peak fractions detected at 276 nm were collected manually. The sample contained multiple immunoreactive fragments of OC, which eluted between 70 min (35% AcN), and 82 min (48% AcN) (Fig. 4). Fractions containing 1.4 - 19.5 µg/ml of immunoreactive uhOC were subjected to further analysis.

## Characterization of osteocalcin fragments

HPLC fractions were analyzed by the two-site immunoassays #7, #9 and #4 as  
5 before and fractions containing immunoreactive uhOC fragments were subjected to MALDI-TOF mass spectrometry and N-terminal amino acid sequencing. The molecular masses of the prominent ions in mass spectrometry were 2778, 2814, 2930 and 3005. Fractions 44 (M=2814) and 46 (M=2930) contained enough material for the N-terminal sequence analysis. The sequence obtained from fraction  
10 44 matches with hOC starting from residue Gly(7). Taking into account the experimental mass 2814, the fragment spans residues 7-30, with  $\gamma$ -carboxylated residues at positions 17, 21 and 24 giving a calculated mass of 2812 (Fig. 5 A).  $\gamma$ -carboxylation of the Glu residues is further supported by the fact that  $\gamma$ -carboxylated Glu residues are known not to give signal using the sequencing technique in  
15 question (Cairns et al. (1991) Anal Biochem. 199, 93-97). Fraction 46 was subjected to trypsin digestion to demonstrate that the fragment can be cleaved as expected (after Arg residue). In addition, the determined N-terminal sequence matches with hOC starting from residue Leu(6). The determined mass of the N-terminal part of the fragment cleaved with trypsin was 1566 and in accordance with  
20 the expected mass (1565 with  $\gamma$ -carboxylated Glu 17). According to the determined mass of fraction 46 before trypsin cleavage (2930, Fig 5B) the fragment spans residues 6-30 of hOC with three  $\gamma$ -carboxylated residues as above (calculated mass 2925). The ion species with masses 2778 (Fig. 5 C) and 3005 (Fig. 5 D)  
represent close structural variants of the same hOC region, based on  
25 immunoreactivity, chromatographic behaviour and molecular mass. Such structural variability can be caused by partial lack of  $\gamma$ -carboxylation or additional 1-2 residues, and/or combinations of both. The characteristics of the fragments have been described in figure 5 E. In addition to immunoassay #7, also assay #9 recognize effectively these forms of urine osteocalcin. Epitope of #4 differs slightly from

epitope recognized by the combination #7 and #9 because the combination could not recognize the 7-30 fragment but could detect the fragment which mass was 3005. Urine may contain shorter hOC fragments which remain to be characterized.

5

## 6. Determination of osteocalcin concentrations in serum and urine panels

### Materials and equipment

10 FSH concentration of serum samples was measured by Delfia® hFSH assay (Wallac, Turku, Finland). The creatinine concentration in urine samples was measured using AU OLYMPUS 510 equipment according to manufacturer's protocols. The protocols of the shOC and uhOC assays have been described in section 5.

### 15 Subjects and sample collection

Clinical evaluation of the assays was performed with serum and urine samples collected between 8 and 11 o'clock in the morning from 58 pre-, 9 peri- and 20 postmenopausal women, 12 postmenopausal women with hormone replacement therapy (HRT) and 16 pubertal girls. In addition to female panel, also a male panel was collected consisting of 46 adult men and 19 pubertal boys. The serum samples were allowed to clot for 30 min. at room temperature before centrifuging and then immediately aliquoted and stored at -70 °C. Collected urine samples were first frozen at -70 °C and then stored at -20 °C. The women were divided into pre-, peri- and postmenopausal groups according to menstrual status and FSH concentration in serum. The postmenopausal group was further classified into subjects with or without hormone replacement therapy (HRT).

### hOC concentrations in serum and urine samples

Serum samples were measured with intact hOC assay specific for full-length hOC (#2), with total hOC assay recognizing not only the intact hOC, but also the N-

5 terminal midfragment of hOC (#4) and with two assays dependent on the degree of  $\gamma$ -carboxylation of the glutamic acids in hOC (#7 and #9). The urine samples were measured with two  $\gamma$ -carboxylation dependent assay (#7 and #9) and also with assay #4. The urine osteocalcin values used for analysis have been corrected for creatinine.

10

### shOC and uhOC in pubertal subjects compared to adult subjects

In women the hOC values observed in serum samples were six to eight fold higher in pubertal girls than in adults. In urine, the hOC concentrations were twelve to

15 sixteen fold higher when comparing the pubertal group to the adults. (Fig. 6.). In men the increase was five fold in serum and eight to eleven fold in urine. Although, the hOC concentration level observed by the assay # 4 is approximately five fold lower than the level observed by assays # 7 or # 9, the concentrations differ significantly between examined groups. All increases were highly significant ( $p <$

20 0.001). The accurate values have been summarized in the Table 3.

Table 3. The difference in hOC concentrations between pubertal and adult males and females.

group	shOC #2	shOC #4	shOC #7	shOC #9	uhOC #4	uhOC #7	uhOC #9
female	6.3	7.8	6.9	6.2	16.5	12.3	12.5
male	4.9	4.7	4.8	4.9	10.8	8.2	8.3

25

### shOC and uhOC in different menopausal groups

The statistically significant increase in hOC concentrations in serum was observed in menopause (40 to 48 %). Interestingly, in urine samples the increase in hOC concentration was as high as 75 % and 79 % as measured with assays #7 and #9, respectively ( $p < 0.001$ ). The increase of urine hOC between the pre- and postmenopausal groups was even higher when measured with assay #4 (125 %,  $p < 0.001$ ). hOC concentrations in postmenopausal subjects on HRT decreased to concentrations indistinguishable from the premenopausal group with every hOC assay in both serum and urine specimens. Statistically significant decreases (30 to 46 %) in serum concentrations were seen depending on the assay used. However, the observed decrease in urine samples was over 50 %. (Fig. 7 A and B.). Although, the hOC concentration level observed by the assay # 4 is approximately five fold lower than the level observed by assays # 7 or # 9, the concentrations differ significantly between examined groups. The discriminatory power of each assay has been summarized in Table 4.

**Table 4.** Percentual differences and statistical significancies between menopausal groups as measured by hOC IFMAs in serum and urine samples.

20

	shOC #2	shOC #4	shOC #7	shOC #9	uhOC #4	uhOC #7	uhOC #9
Increase in menopause (%)	42	48	43	40	125	75	79
p-value	0.0008	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001
Decrease in HRT (%)	46	30	35	33	57	51	57
p-value	0.0021	0.0161	0.0065	0.0086	0.0352	0.0133	0.0074

Although the assays definitely detected different forms of circulating hOC, their performance in measuring the serum panel was almost identical. The IFMAs were

even more effective in discriminating postmenopausal group from premenopausal group and also postmenopausal group under HRT from postmenopausal control group when measured in urine samples.

5 The serum hOC assays correlated well with each other. On the contrary, differences between urine assays were observed. As explained in section 5 the assay #4 recognizes a slightly different fragment in urine than assays #7 and #9. This might explain the weaker correlation between the assays #4 and #7 ( $r = 0.843$ , Fig. 8 A) than between assays #7 and #9 ( $r = 0.976$ , Fig. 8B) as measured in the urine

10 samples. When comparing the hOC values in urine and serum samples the correlation was remarkably lower although measured by the same Mab combination. Correlations between urine and serum samples in assay #7 ( $r = 0.625$ ) and assay #4 ( $r = 0.427$ ) are illustrated in Fig. 8 C and D, respectively. All the correlations were significant ( $p < 0.001$ ) and have been summarized in Table 5.

15

Table 5. Correlations between the hOC assays as measured in serum and urine samples from adult females. All the correlations are significant ( $p < 0.001$ ).

	shOC #2	shOC #4	shOC #7	shOC #9	uhOC #4/creat	uhOC #7/creat	uhOC #9/creat
shOC #2	1.000	.823	.867	.870	.422	.521	.558
shOC #4	.823	1.000	.932	.929	.427	.555	.572
shOC #7	.867	.932	1.000	.989	.504	.625	.648
shOC #9	.870	.929	.989	1.000	.519	.653	.671
uhOC #4/creat	.422	.427	.504	.519	1.000	.843	.824
uhOC #7/creat	.521	.555	.625	.653	.843	1.000	.976
uhOC #9/creat	.558	.572	.648	.671	.824	.976	1.000

20

It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the specialist in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are

25 illustrative and should not be construed as restrictive.

## CLAIMS

1. An isolated osteocalcin fragment derived from human urine, said fragment  
characterized in that at least one of the glutamic acids in the position 17, 21 and 24  
5 of the amino acid sequence

Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-  
 Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-  
 Glu-Pro-Arg-Arg-Glu-Val-Cys-Glu-Leu-  
 Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-  
 Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-  
 Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val

is gamma-carboxylated.

2. The fragment according to claim 1 characterized in that the fragment spans from  
25 the amino acid in position 7 to the amino acid in position 30 of the amino acid  
sequence described in claim 1, and that all three glutamic acids in the positions 17,  
21 and 24 of said sequence are gamma-carboxylated.

3. The fragment according to claim 1 characterized in that the fragment spans from  
30 the amino acid in position 6 to the amino acid in position 30 of the amino acid  
sequence described in claim 1, and that all three glutamic acids in the positions 17,  
21 and 24 of said sequence are gamma-carboxylated.

4. A monoclonal antibody or recombinant antibody fragment having the capability of binding the human gamma-carboxylated osteocalcin fragment according to claim 1, 2 or 3, characterized by the specificity to epitopes that have been identified on the gamma-carboxylated fragment of osteocalcin, wherein said fragment spans either

5           i) from the amino acid in position 7 to the amino acid in position 30, or  
             ii) from the amino acid in position 6 to the amino acid in position 30  
of the amino acid sequence described in claim 1, and that all three glutamic acids in the positions 17, 21 and 24 of said sequence are gamma-carboxylated.

10 5. A cell line producing the monoclonal antibody according to claim 4.

6. A non-competitive immunoassay for quantitative determination of a gamma-carboxylated osteocalcin fragment according to claim 1 characterized in that a sample containing said fragment is exposed to two monoclonal antibodies or 15 recombinant antibody fragments which bind said gamma-carboxylated osteocalcin fragment.

7. The immunoassay according to claim 6 characterized by employing monoclonal antibodies or recombinant antibody fragments specific to epitopes that have been 20 identified on the gamma-carboxylated fragment of osteocalcin, wherein said fragment spans either

25           i) from the amino acid in position 7 to the amino acid in position 30, or  
             ii) from the amino acid in position 6 to the amino acid in position 30  
of the amino acid sequence described in claim 1, and that all three glutamic acids in the positions 17, 21 and 24 of said sequence are gamma-carboxylated.

8. The immunoassay according to claim 6 or 7 characterized in that the non-competitive immunoassay is carried out in either a one-step or a two-step incubation procedure.

30 -08- 1999

32

9. The immunoassay according to claim 6 or 7 characterized in that the two monoclonal antibodies employed are the antibodies 2H9 and 6F9 that recognize the C-terminal and N-terminal epitopes on the fragment which was determined to be  
5 3005.

10. The immunoassay according to claim 6 or 7 characterized in that the two monoclonal antibodies employed are the antibodies 6F9 and 1C4 that recognize the N-terminal and the C-terminal epitopes on the measured osteocalcin fragments (6-  
10 30 or 7-30).

11. The immunoassay according to claim 6 or 7 characterized in that the two monoclonal antibodies employed are the antibodies 6F9 and 3H8 that recognize the N-terminal and the C-terminal epitopes on the measured osteocalcin fragments (6-  
15 30 or 7-30).

12. A method for the measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders in an individual,  
characterized by quantitative determination of a fragment according to any of the  
20 claims 1 to 3.

13. The method according to claim 12 characterized in that an immunoassay according to any of the claims 6 - 11 is employed.

5' Tyr Leu Tyr Gln Trp Leu Gly Ala Pro Val Pro  
TAC CTG TAT CAA TGG CTG GGA GCC CCA GTC CCC  
Tyr Pro Asp Pro Leu Glu Pro Arg Arg Glu Val  
TAC CCG GAT CCC CTG GAG CCC AGG AGG GAG GTG  
Cys Glu Leu Asn Pro Asp Cys Asp Glu Leu Ala  
TGT GAG CTC AAT CCG GAC TGT GAC GAG TTG GCT  
Asp His Ile Gly Phe Gln Glu Ala Tyr Arg Arg  
GAC CAC ATC GGC TTT CAG GAG GCC TAT CGG CGC  
Phe Tyr Gly Pro Val stop PstI  
TTC TAC GGC CCG GTC TAA CTG CAG ATGC 3'

FIG. 1A




FIG. 1B

2/13

FIG. 2B




FIG. 2A




FIG.3




FIG. 4

5/13





FIG. 5A

6/13

FIG. 5B



7/13





FIG. 5C

8/13

FIG. 5D




9 / 13

fraction number	fragment length	determined mass	amino acid sequence	$\gamma$ -carboxylated glutamic acid residues
43	N. D.	2778	not determined	1-3 residues
44	7-30	2814	GAPVVPYPDPLGlaPRRGlaVCGlaLNPD	17, 21 and 24
46	6-30	2930	LGAPVVPYPDPLGlaPRRGlaVCGlaLNPD	17, 21 and 24
47	N.D.	3005	not determined	1-3 residues

FIG. 5E

10/13



11/13




FIG. 7A




FIG. 7B

12/13




FIG. 8A




FIG. 8B

13/13




FIG. 8C




FIG. 8D

Attorney Docket No. \_\_\_\_\_

**Declaration and Power of Attorney  
For Patent Application  
(Sole/Joint)**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought, on the invention entitled Isolated osteocalcin fragments

the specification of which (*Check One*)

\_\_\_\_\_ is attached hereto.

X was filed on 24 June 1998 as  
[ ] Application Serial No. \_\_\_\_\_  
[X] International Application No. PCT/ FI98/00550  
and was amended on 30 August 1999.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

**PRIOR FOREIGN APPLICATION(S)**

			<b>Priority Claimed</b>
<u>973371</u> (Number)	<u>Finland</u> (Country)	<u>15 August 1997</u> (Day/Month/Year Filed)	Yes: <u>X</u> No: _____
<u>                  </u> (Number)	<u>                  </u> (Country)	<u>                  </u> (Day/Month/Year Filed)	Yes: _____ No: _____
<u>                  </u> (Number)	<u>                  </u> (Country)	<u>                  </u> (Day/Month/Year Filed)	Yes: _____ No: _____

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose

material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

(Application Serial No.)	(Filing Date)	(Status)
(Application Serial No.)	(Filing Date)	(Status)

I or we hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to ROTHWELL, FIGG, ERNST & KURZ, P.C., 555 13th Street, N.W., Washington, D.C. 20004

16 &  
cont'd.

G. Franklin Rothwell, Reg. No. <u>18,125</u>	Michael G. Sullivan, Reg. No. <u>35,377</u>
E. Anthony Figg, Reg. No. <u>27,195</u>	Mark I. Bowditch, Reg. No. <u>40,315</u>
Barbara G. Ernst, Reg. No. <u>30,377</u>	Robert J. Jondle, Reg. No. <u>33,915</u>
George R. Repper, Reg. No. <u>31,414</u>	Moon Soo Lee, Reg. No. <u>37,377</u>
Bart G. Newland, Reg. No. <u>31,282</u>	Kenneth M. Fagin, Reg. No. <u>37,615</u>
Vincent M. DeLuca, Reg. No. <u>32,408</u>	Stephen B. Parker, Reg. No. <u>36,631</u>
Celine Jimenez Crowson, Reg. No. <u>40,357</u>	Michael J. Donnelly, Reg. No. <u>38,126</u>
Joseph A. Hynds, Reg. No. <u>34,627</u>	Minaksi Bhatt, Reg. No. <u>35,447</u>

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of Sole or First Inventor	Inventor's Signature	Date
Jukka Hellman		21.12.1999
Residence	Amiraalistonkatu 5 C 12	Citizenship
		Finnish
Post Office Address	FIN-20100 Turku, Finland FIX	
Full Name of Second Joint Inventor, if any	Inventor's Signature	Date
Sanna-Maria Käkönen		21.12.1999
Residence	Murtomaantie 39	Citizenship
		Finnish
Post Office Address	FIN-20300 Turku, Finland FIX	
Full Name of Third Joint Inventor, if any	Inventor's Signature	Date
Matti Karp		20.12.1999
Residence	Kampakatu 1	Citizenship
		Finnish
Post Office Address	FIN-20660 Littoinen, Finland FIX	
Full Name of Fourth Joint Inventor, if any	Inventor's Signature	Date
Timo Lövgren		21.12.1999
Residence	Yliopistonkatu 2 H 155	Citizenship
		Finnish
Post Office Address	FIN-20100 Turku, Finland FIX	
H. Kalervo Väänänen		Patent Application Declaration 22 Dec 1999 page 2 of 2
Kannuskatu 3 J 143		Finnish citizen
FIN-20880 Turku, Finland FIX		
Kim Pettersson		20.12.1999
Tiilenteekäytävä 14 E 20, FIN-20810 Turku, Finland FIX		Finnish citizen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of )  
                               )  
                               )  
Jukka HELLMAN et al.     ) U.S. National Phase  
                               )  
                               ) PCT/FI98/00550  
Serial No. (to be assigned) )  
                               )  
                               ) Intl. Filing Date: 24.06.1998  
Filed: 07 January 2000     )  
                               )  
For: ISOLATED OSTEOCALCIN )  
                               )  
                               ) FRAGMENTS  
                               )

ASSOCIATE POWER OF ATTORNEY

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Please recognize the following individuals as associate attorneys in the above application, filed concurrently herewith.

Jeffrey L. Ihnen, Reg. No. 28,957  
Stephen A. Saxe, Reg. No. 38,609  
ROTHWELL, FIGG, ERNST & KURZ, P.C.  
555 13th Street, N.W., Suite 701-E  
Washington, D.C. 20004

Respectfully submitted,

By Barbara G. Ernst  
Barbara G. Ernst, Registration No. 30,377  
Attorney for Applicants  
ROTHWELL, FIGG, ERNST & KURZ, p.c.  
Suite 701-E, 555 13th Street, N.W.  
Washington, D.C. 20004  
Telephone: (202)783-6040

Dated: 18 January 2000  
2328-115usn.apa